{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-106265","form_type":"8-K","ticker":"TTRX","cik":"0002023016","company_name":"Turn Therapeutics Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.349198+00:00","generated_at":"2026-05-17T00:44:46.895915+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Turn Therapeutics Appoints Andrew Scott as VP of Corporate Communications","bullets":["Andrew Scott appointed VP of Corporate Communications effective November 4, 2025.","Scott will oversee IR, capital markets strategy, and licensing partnerships.","He joins from ThinkEquity LLC, where he was Managing Director of Investment Banking.","Scott has helped raise approximately $3 billion across life-sciences transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-106265","json":"https://secwatch.observer/filing/0001213900-25-106265.json","markdown":"https://secwatch.observer/filing/0001213900-25-106265.md","text":"https://secwatch.observer/filing/0001213900-25-106265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025106265/0001213900-25-106265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023016/000121390025106265/ea0264083-8k_turn.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:44:46.895915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}